As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.

Recent calls in Congress and by the Select Committee on the Chinese Communist Party have intensified pressure to restrict U.S. investment and partnerships in China's biopharmaceutical and biotech firms, including major deals like Bristol Myers Squibb’s $15 billion pact with Hengrui Pharma.
Passage of the BioSecure Act and related measures in the Senate has barred federal agencies from contracting with certain Chinese biotech firms deemed national security risks, raising concerns among U.S. and global biotech companies about chilling collaboration and threatening drug supply chains.
China has sharply criticized Washington’s moves as protectionist and harmful to global innovation, while a bipartisan U.S. commission warns America risks losing its long‑held lead in biotech to China absent aggressive public investment and tighter export and investment controls.